A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KN-026 (Primary)
Indications Advanced breast cancer; Gastric cancer
Focus Adverse reactions; First in man
Sponsors Alphamab Oncology

Most Recent Events

01 Nov 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Jun 2020.
06 Jun 2019 Results published in the Alphamab Oncology Media Release
28 Sep 2018 Status changed from not yet recruiting to recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight